NCT04722640

Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Istituto Clinico Humanitas · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Approximately 80 patients affected by moderate to severe psoriasis will be screened for the presence of LL37( and ADAMTSL5 autoreactive T-cells in their blood at Day 0. Patients whose lymphocytes reacted with proliferation to LL37 or ADAMTSL5 will receive SKYRIZI (Risakizumab) at Day 1, week 4, 16, 28, 40. LL37 and ADAMTSL5-specific T-cell responses will be evaluated at Day 0, week 16, week 28 and week 52. Each patient will be followed for 52 weeks.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	SKYRIZI	SKYRIZI

Timeline

• Start date: 2021-01-25
• Primary completion: 2022-01-31
• Completion: 2022-01-31
• First posted: 2021-01-25
• Last updated: 2021-01-29